In the early morning session of today's FDA Panel conference on the long term use of bisphosphonates, like the drug Fosamax, the FDA's Lead Medical Officer Fatmatta Kuyateh, M.D. indicated that radiographic findings consistent with atypical femur fractures case have been associated with bisphosphonate use.
It appears that the collection of data to firmly track the association with the duration of use of the drug is still ongoing. Dr. Fatmatta's presentation at the conference also showed that the prevalence of ONJ (Osteonecrosis of the Jaw) may increase with increased duration of exposure to oral bisphosphonate. Further presentations are expected later today from Merck, the manufacturer of Fosamax.
Today's FDA sponsored conference is a Joint Meeting of the Reproductive Health Drugs Advisory Committee and the Drug Safety and Risk Management Advisory Committee Meeting Announcement, taking place University of Maryland University College. The committees are discussing the benefits and risks of long-term bisphosphonate use for the treatment of osteoporosis given the emergence of the safety concerns of osteonecrosis of the jaw (jawbone death) and atypical femur fractures (unusual broken thigh bone) that may be associated with the long-term use of Fosamax.